Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study

Paolo Corradini, Chiara Agrati, Giovanni Apolone, Alberto Mantovani, Diana Giannarelli, Vincenzo Marasco, Veronica Bordoni, Alessandra Sacchi, Giulia Matusali, Carlo Salvarani, Pier Luigi Zinzani, Renato Mantegazza, Fabrizio Tagliavini, Maria Teresa Lupo-Stanghellini, Fabio Ciceri, Silvia Damian, Antonio Uccelli, Daniela Fenoglio, Nicola Silvestris, Fausto Baldanti, Giulia Piaggio, Gennaro Ciliberto, Aldo Morrone, Franco Locatelli, Valentina Sinno, Maria Rescigno, Massimo Costantini
doi: https://doi.org/10.1101/2022.01.12.22269133
Paolo Corradini
1Department of oncology and hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy
2School of Medicine, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chiara Agrati
3Cellular Immunology Laboratory, National Institute for Infectious Diseases L Spallanzani – IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chiara.agrati@inmi.it
Giovanni Apolone
4Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto Mantovani
5Humanitas Scientific Directorate, IRCCS Humanitas, Clinical and Research Center, Rozzano, Italy
6Department of Biomedical Sciences, Humanitas University, Milan, Italy,
7William Harvey Research Institute, Queen Mary University, London, United Kingdom,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana Giannarelli
8Biostatistical Unit, Istituto Nazionale Tumori Regina Elena IRCCS - IFO, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincenzo Marasco
1Department of oncology and hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy
2School of Medicine, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Veronica Bordoni
3Cellular Immunology Laboratory, National Institute for Infectious Diseases L Spallanzani – IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandra Sacchi
3Cellular Immunology Laboratory, National Institute for Infectious Diseases L Spallanzani – IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giulia Matusali
9Virology Laboratory, National Institute for Infectious Diseases L Spallanzani – IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlo Salvarani
10Unità di Reumatologia, Azienda USL-IRCCS, Reggio Emilia, Italy
11Unità di Reumatologia, Università degli Studi di Modena e Reggio Emilia, Modena
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pier Luigi Zinzani
12Istituto di Ematologia “Seràgnoli”, Azienda Ospedaliero-Universitaria di Bologna - IRCCS, Bologna, Italy
13Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renato Mantegazza
14Neuromuscular Diseases and Neuroimmunology Unit, Fondazione IRCCS Isitituto Neurologico Carlo Besta, Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabrizio Tagliavini
15Scientific Directorate, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Teresa Lupo-Stanghellini
16Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabio Ciceri
17Scientific Directorate, IRCSS San Raffaele Scientific Institute, Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvia Damian
1Department of oncology and hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Uccelli
18Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health and Center of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy,
19Biotherapy Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Fenoglio
19Biotherapy Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
20Centre of Excellence for Biomedical Research and Department of Internal Medicine, University of Genoa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Silvestris
21Medical Oncology Department, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy
22Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro”, Bari, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fausto Baldanti
23Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo
24Department of Clinical, Surgical, Diagnostics and Pediatric Sciences, University of Pavia, Pavia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giulia Piaggio
25SAFU Unit IRCCS Regina Elena, National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gennaro Ciliberto
26Scientific Directorate IRCCS Regina Elena, National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aldo Morrone
27Scientific Directorate, San Gallicano Dermatological Institute IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franco Locatelli
28Department of Pediatric Hematology and Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù
29Department of Gynecology-Obstetrics and Pediatrics, University “La Sapienza”, Roma, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valentina Sinno
1Department of oncology and hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Rescigno
6Department of Biomedical Sciences, Humanitas University, Milan, Italy,
30Mucosal Immunology and Microbiota Unit, IRCCS Humanitas Clinical and Research Center, Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chiara.agrati@inmi.it
Massimo Costantini
31Scientific Directorate, Azienda Unita Sanitaria Locale (USL)-IRCCS Reggio Emilia, Reggio Emilia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Patients with solid or hematological tumors, neurological and immune-inflammatory disorders represent potentially fragile subjects with increased risk to experience severe COVID-19 and inadequate response to SARS-CoV2 vaccination.

Methods We designed a prospective Italian multicentric study to assess humoral and T-cell response to SARS-CoV2 vaccination in patients (n=378) with solid tumors (ST), hematological malignancies (HM), neurological (ND) and immuno-rheumatological diseases (ID). The immunogenicity of primary vaccination schedule and of the booster dose were analyzed.

Results Overall, patient seroconversion rate after two doses was 62.1%. A significant lower rate was observed in HM (52.4%) and ID (51.9%) patients compared to ST (95.6%) and ND (70.7%); a lower median level of antibodies was detected in HM and ID versus the others (p<0.0001). A similar rate of patients with a positive SARS-CoV2 T-cell response was observed in all disease groups, with a higher level observed in the ND group. The booster dose improved humoral responses in all disease groups, although with a lower response in HM patients, while the T-cell response increased similarly in all groups. In the multivariable logistic model, the independent predictors for seroconversion were disease subgroups, type of therapies and age. Notably, the ongoing treatment known to affect the immune system was associated with the worst humoral response to vaccination (p<0.0001), but had no effects on the T-cell responses.

Conclusions Immunosuppressive treatment more than disease type per se is a risk factor for low humoral response after vaccination. The booster dose can improve both humoral and T-cell response.

Article’s main point

  • - Lower rate of seroconversion was observed in fragile patients as compared to healthy controls

  • - The booster dose improves humoral and T-cell response in all fragile patient groups

  • - Immunosuppressive treatment was associated with the worst humoral response to vaccination, but had no effects on T-cell responses.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the Italian ministry of Health

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Italian Regulatory Agency (AIFA) and by the Ethics Committee of IRCCS L. Spallanzani (code 304, 2021).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 13, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study
Paolo Corradini, Chiara Agrati, Giovanni Apolone, Alberto Mantovani, Diana Giannarelli, Vincenzo Marasco, Veronica Bordoni, Alessandra Sacchi, Giulia Matusali, Carlo Salvarani, Pier Luigi Zinzani, Renato Mantegazza, Fabrizio Tagliavini, Maria Teresa Lupo-Stanghellini, Fabio Ciceri, Silvia Damian, Antonio Uccelli, Daniela Fenoglio, Nicola Silvestris, Fausto Baldanti, Giulia Piaggio, Gennaro Ciliberto, Aldo Morrone, Franco Locatelli, Valentina Sinno, Maria Rescigno, Massimo Costantini
medRxiv 2022.01.12.22269133; doi: https://doi.org/10.1101/2022.01.12.22269133
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study
Paolo Corradini, Chiara Agrati, Giovanni Apolone, Alberto Mantovani, Diana Giannarelli, Vincenzo Marasco, Veronica Bordoni, Alessandra Sacchi, Giulia Matusali, Carlo Salvarani, Pier Luigi Zinzani, Renato Mantegazza, Fabrizio Tagliavini, Maria Teresa Lupo-Stanghellini, Fabio Ciceri, Silvia Damian, Antonio Uccelli, Daniela Fenoglio, Nicola Silvestris, Fausto Baldanti, Giulia Piaggio, Gennaro Ciliberto, Aldo Morrone, Franco Locatelli, Valentina Sinno, Maria Rescigno, Massimo Costantini
medRxiv 2022.01.12.22269133; doi: https://doi.org/10.1101/2022.01.12.22269133

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (164)
  • Allergy and Immunology (417)
  • Anesthesia (93)
  • Cardiovascular Medicine (867)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (398)
  • Epidemiology (8597)
  • Forensic Medicine (4)
  • Gastroenterology (391)
  • Genetic and Genomic Medicine (1775)
  • Geriatric Medicine (170)
  • Health Economics (376)
  • Health Informatics (1252)
  • Health Policy (625)
  • Health Systems and Quality Improvement (472)
  • Hematology (198)
  • HIV/AIDS (380)
  • Infectious Diseases (except HIV/AIDS) (10355)
  • Intensive Care and Critical Care Medicine (554)
  • Medical Education (193)
  • Medical Ethics (51)
  • Nephrology (214)
  • Neurology (1692)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (330)
  • Occupational and Environmental Health (451)
  • Oncology (934)
  • Ophthalmology (265)
  • Orthopedics (104)
  • Otolaryngology (172)
  • Pain Medicine (115)
  • Palliative Medicine (40)
  • Pathology (256)
  • Pediatrics (541)
  • Pharmacology and Therapeutics (257)
  • Primary Care Research (210)
  • Psychiatry and Clinical Psychology (1788)
  • Public and Global Health (3877)
  • Radiology and Imaging (629)
  • Rehabilitation Medicine and Physical Therapy (324)
  • Respiratory Medicine (525)
  • Rheumatology (208)
  • Sexual and Reproductive Health (171)
  • Sports Medicine (159)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)